CN113264975B

CN113264975B - An extract with antiinflammatory activity extracted from fructus Rosae Normalis rhizome and its application

Info

Publication number: CN113264975B
Application number: CN202110383461.1A
Authority: CN
Inventors: 杨小生; 李良群; 王瑜; 李齐激; 梁勇; 王丽; 罗忠圣; 李立郎; 杨娟
Original assignee: Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Current assignee: Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority date: 2021-04-09
Filing date: 2021-04-09
Publication date: 2023-10-20
Anticipated expiration: 2041-04-09
Also published as: CN113264975A

Abstract

The invention discloses an extract with anti-inflammatory activity extracted from the rootstocks of Rosa roxburghii and application thereof, wherein the extract comprises compounds 1,2, 3, 4, 5, 6 and 7. Using chloroform: methanol=30:1, 20:1,10:1 to give compounds 1,2, 3; using chloroform: methanol=8:1 elution to give compound 5; and purifying by Sephdex-LH-20 gel to obtain compounds 4, 6 and 7. The compounds 4, 6 and 7 disclosed by the invention are separated from the root of the roxburgh rose for the first time; the seven compounds have good anti-inflammatory activity on in vitro cell anti-inflammatory activity screening by RAW 264.7.

Description

An extract with antiinflammatory activity extracted from fructus Rosae Normalis rhizome and its application

Technical Field

The invention belongs to the field of natural medicines, and particularly relates to an extract with anti-inflammatory activity extracted from rhizomes of rosa roxburghii tratt and application thereof.

Background

Rosa roxburghii (Rosa roxbunghii Tratt) is a fruit of filature flower of Rosa genus plant of Rosaceae family, and is mainly distributed in southwest area in China with the most noble state among them, and is also called fructus Rosae Normalis, etc. (Navowels, etc. 2015). The roxburgh rose has higher medicinal value, and can be used as a medicament for roots, stems, leaves, flowers, fruits and the like (Song Demo, liu Qinggong, 2012), has sour and astringent taste, has the effects of strengthening spleen to promote digestion and astringing to arrest diarrhea, and is mainly used for treating diseases such as food stagnation, abdominal distention, diarrhea and the like (Guizhou province medicine administration, 2003). Wherein the fructus Rosae Normalis rhizome decoction has effects of treating acute bacillary dysentery and chronic gastric ulcer (Chen Yunzhi, liu Anying, 2007; chen Jianhua, etc., 2001). The fructus Rosae Normalis rhizome decoction is taken by people in Yao nationality in Guizhou Libo region to treat digestive system diseases and leukorrhagia, has good therapeutic effect on diarrhea of various animals such as pig, cattle and sheep (An Xiaohao, 2015; yu Yuesheng, 2016; luo Maochuan, bai Xiancai, 2008; feng Hongqian, 1984), has good therapeutic effect on the above diseases, and can cause inflammation in the course of the generation and development of the diseases, and the compounds obtained by separation are screened for anti-inflammatory activity for further elucidating the anti-inflammatory active substance basis of fructus Rosae Normalis rhizome.

Disclosure of Invention

The invention aims to provide an extract with anti-inflammatory activity extracted from the rhizomes of rosa roxburghii tratt, a preparation method thereof and application of the extract in preparing anti-inflammatory medicines.

The aim and the main technical problems are achieved by adopting the following technical scheme: an extract having anti-inflammatory activity extracted from the rootstock of rosa roxburghii, said extract comprising: rosin (1), wild rose glycoside (2), rosacic acid (3), beta-D-glucopyranosyl- (2 a- > 1 b) -2 a-O-beta-L-arabinopyranosyl- (2 b- > 1 c) -2 b-O-beta-L-arabinopyranosyl- (2 c- > 1D) -2 c-O-beta-L-arabinopyranosyl- (2D- > 1 e) -2D-O-beta-L-arabinopyranosyl- (2 e- > 1 f) -2 e-O-beta-L-arabinopyranosyl- (4), catechin (5), 3-O-methylellagic acid' -O-beta-D-xylopyranosyl (6), 3-O-methylellagic acid-4-O-alpha-L-rham-nopranoside (7) seven compounds with the structural formulas of (1), (2), (4) and (6), respectively, and the following steps of washing, preparing a dry extract with ethanol, concentrating the extract by reflux extraction under reduced pressure, filtering, concentrating the extract with ethanol, extracting under 60% ethanol, concentrating, extracting under reduced pressure, extracting under reflux, and concentrating the extract with 80% ethanol, extracting under reflux, and concentrating: methanol=10:1, 5:1,1:1,0:1 as eluent, yielding four fractions, wherein fraction a, fraction B, fraction C, fraction D; part C was then purified with chloroform: methanol=30:1, 20:1,10:1 to afford compound 1 and compound 2; part B was prepared with chloroform: methanol=20:1, 10:1 gradient elution, concentration under reduced pressure, recrystallization to obtain compound 3; part D was purified with chloroform: methanol=8:1 elution to give compound 5; and purifying other fractions by Sephadex-LH-20 gel chromatographic column chromatography to obtain a compound 4, a compound 6 and a compound 7.

The root and stem of the Rosa roxburghii is Rosa roxburghii No. 5.

The compounds 1,2, 3, 4, 5, 6 and 7 obtained in the steps have obvious inhibition effect on NO released by mouse macrophage RAW264.7 induced by LPS, and are applied to anti-inflammatory drugs.

When the compounds 1,2, 3, 4, 5, 6 and 7 are used as medicaments, they can be used directly or in the form of a pharmaceutical composition containing 0.1 to 99% of the compounds, the balance being pharmaceutically acceptable carriers or excipients.

The pharmaceutically acceptable carriers or excipients are one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical formulation adjuvants.

The pharmaceutical composition is used in the form of a unit weight dosage.

The dosage form of the pharmaceutical composition is as follows: injection, suspension, emulsion, solution, syrup, tablet, capsule, granule, spray and aerosol.

Compared with the prior art, the invention has obvious advantages and beneficial effects. According to the technical scheme, the extract obtained from the rhizomes of the rosa roxburghii tratt has obvious inhibition effect on NO released by mouse macrophage RAW264.7 induced by LPS, has treatment effect on various diseases caused by inflammation, and has important application prospect in developing the extract into anti-inflammatory active medicaments.

Drawings

FIG. 1 is a structural formula of compounds 1,2, 3, 4, 5, 6 and 7.

FIG. 2 is the effect of compounds 1,2, 3, 4, 5, 6 and 7 on mouse macrophage proliferation.

FIG. 3 is the effect of NO expression on RAW264.7 cells.

Detailed Description

The following detailed description of the invention refers to an anti-inflammatory extract extracted from the rootstocks of Rosa roxburghii, and its specific embodiments, features and effects.

An extract having anti-inflammatory activity extracted from the rootstock of rosa roxburghii, said extract comprising: rosa roxburghii glycoside (1), rosa roxburghii glycoside (2), rosa acid (3), beta-D-glucopyranosyl- (2 a- > 1 b) -2 a-O-beta-L-arabinopyranosyl- (2 b- > 1 c) -2 b-O-beta-L-arabinopyranosyl- (2 c- > 1D) -2 c-O-beta-L-arabinopy-ranosyl- (2D- > 1 e) -2D-O-beta-L-arabinopyranosyl- (2 e- > 1 f) -2 e-O-beta-L-arabinopyranosyl (4), catechin (5), 3-O-methylellagic acid' -O-beta-D-xylopyranosyl (6), seven compounds of 3-O-methylellagic acid-4-O-alpha-L-rham-noparanoside (7) with the structural formulas of (1), (2), (3), 4, 5, 6 and 7 are respectively prepared by cleaning fresh roots and stems of Rosa roxburghii, cutting, reflux-extracting with 80% ethanol for 3 times, filtering and combining the extracts, concentrating under reduced pressure until no alcohol smell exists, concentrating at 60 ℃ to obtain extract, separating samples by silica gel column chromatography, and selecting chloroform: methanol=10; 1,5:1,1:1,0:1 as eluent to obtain four parts, wherein part A, part B, part C and part D; part C was then purified with chloroform: methanol=30:1, 20:1,10:1 to afford compound 1 and compound 2; part B was prepared with chloroform: methanol=20:1, 10:1 gradient elution, concentration under reduced pressure, recrystallization to obtain compound 3; part D was purified with chloroform: methanol=8:1 elution to give compound 5; and purifying other fractions by Sephadex-LH-20 gel chromatographic column chromatography to obtain a compound 4, a compound 6 and a compound 7.

The root and stem of the Rosa roxburghii is Rosa roxburghii No. 5.

The pharmaceutical composition is used in the form of a unit weight dosage.

Example 1

Washing fresh fructus Rosae Normalis rhizome (40 kg), cutting, reflux-extracting with 80% ethanol for 3 times each for 2 hr, filtering, mixing extractive solutions, concentrating under reduced pressure until no alcohol smell exists, transferring to water bath (60deg.C), concentrating to obtain extract 1.15kg, subjecting the extract to primary separation by silica gel column chromatography, and selecting chloroform: methanol=10:1, 5:1,1:1,0:1 as eluent, four fractions were obtained, of which fraction a 11g, fraction b 97g, fraction c 69g, fraction d 263g. Part C was then purified with chloroform: methanol=630:1, 20:1,10:1:1 to afford compound 1 (65 mg) and compound 2 (42 mg); part B was prepared with chloroform: methanol=20:1, 10:1 gradient elution, concentration under reduced pressure, recrystallization to give compound 3 (35 mg); part D was purified with chloroform: methanol=8:1 elution to give compound 5 (40 mg); the other fractions obtained were concentrated under reduced pressure, and then purified by Sephadex-LH-20 gel column chromatography to give Compound 4 (200 mg), compound 6 (25 mg) and Compound 7 (18 mg). .

The map data are as follows:

compound 1: white powder (methanol); ESI-MS m/z 673[ M+Na ]] ⁺ ； ¹ H NMR(600MHz,MeOD)δ：5.35(1H，d，J＝12.0Hz，glc-1)，5.32(1H，br s，H-12)，2.52(1H，s，H-18)，2.65(1H，m，H-3)，1.35(3H，s，CH ₃ -27),1.20(3H，s，CH ₃ -29)，0.98(3H，d，CH ₃ -25)，0.97(3H，d，CH ₃ -23)，0.92(3H，d，J＝9.0Hz，CH ₃ -30)，0.84(3H，s，CH ₃ -23),0.75(3H，s，CH ₃ -24)； ¹³ C NMR(150MHz,MeOD)δ：42.5(C-1)，67.3(C-2)，80.1(C-3)，39.6(C-4)，49.2(C-5)，22.6(C-6)，34.2(C-7)，41.5(C-8)，48.5(C-9)，39.4(C-10)，24.5(C-11)，129.5(C-12)，139.5(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.2(C-18)，73.5(C-19)，43.0(C-20)，27.3(C-21)，38.5(C-22)，29.3(C-23)，16.6(C-24)，17.2(C-25)，19.3(C-26)，24.8(C-27)，178.5(C-28)，27.2(C-29)，17.7(C-30)，95.6(C-1′)，73.5(C-2′)，78.6(C-3′)，71.3(C-4′)，78.5(C-5′)，62.5(C-6′)。

Compound 2: white powder (methanol); ESI-MS m/z 673[ M+Na ]] ⁺ ； ¹ H NMR(600MHz,MeOD)δ：5.35(1H，d，J＝12.0Hz，glc-1)，5.32(1H，br s，H-12)，2.50(1H，s，H-18)，1.32(3H，s，CH ₃ -27)，1.28(3H，s，CH ₃ -29)，1.15(3H，s，CH ₃ -25)，1.05(3H，s，CH ₃ -23)，0.92(3H，d，J＝7.5Hz，CH ₃ -30)，0.80(3H，s，CH ₃ -26),0.75(3H，s，CH ₃ -24)； ¹³ C NMR(150MHz,MeOD)δ：48.2(C-1)，69.5(C-2)，84.2(C-3)，39.2(C-4)，56.5(C-5)，19.7(C-6)，34.0(C-7)，41.5(C-8)，48.6(C-9)，40.6(C-10)，24.8(C-11)，129.5(C-12)，139.7(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.0(C-18)，73.5(C-19)，43.0(C-20)，27.3(C-21)，36.9(C-22)，29.3(C-23)，17.6(C-24)，16.5(C-25)，17.5(C-26)，24.9(C-27)，178.5(C-28)，28.6(C-29)，25.2(C-30)，95.8(C-1′)，73.6(C-2′)，78.2(C-3′)，71.3(C-4′)，78.5(C-5′)，62.3(C-6′)。。

Compound 3: white powder (methanol); ESI-MS m/z 511[ M+Na ]] ⁺ ； ¹ H NMR(600MHz,MeOD)δ：5.30(1H，br s，H-12)，3.91(1H，br d，J＝18.0Hz，H-3)，3.31(1H，overlop，H-2)，2.50(1H，s，H-18)，1.35(3H，s，CH ₃ -27)，1.28(3H，s，CH ₃ -29)，1.1,8(3H，s，CH ₃ -25)，0.98(3H，s，CH ₃ -23)，0.92(3H，d，J＝10.5Hz，CH ₃ -30)，0.85(3H，s，CH ₃ -26),0.75(3H，s，CH ₃ -24)； ¹³ C NMR(150MHz,MeOD)δ：42.3(C-1)，67.2(C-2)，80.2(C-3)，41.2(C-4)，49.3(C-5)，24.5(C-6)，34.0(C-7)，39.3(C-8)，48.2(C-9)，39.5(C-10)，27.2(C-11)，129.3(C-12)，140.0(C-13)，42.8(C-14),29.5(C-15)，26.5(C-16)，48.5(C-17)，55.0(C-18)，73.5(C-19)，43.0(C-20)，19.2(C-21)，36.9(C-22)，39.0(C-23)，29.3(C-24)，17.5(C-25)，16.6(C-26)，27.0(C-27)，182.5(C-28)，24.9(C-29)，16.9(C-30)。

Compound 4: yellow semi-solid (methanol); ESI-MS m/z 840[ M-H ]]-； ¹ H NMR(600MHz,MeOD)δ：4.45(d，H-1a)，3.96(dd，H-2a)，3.48(m，H-3a)，3.83(m，H-4a)，3.95(m，H-5a)，3.15(d，H-6a)，5.08(d，H-1b)，4.03(dd，H-2b)，3.45(m，H-3b)，3.85(m，H-4b)，3.22(d，H-5b)，4.63(d，H-1c)，3.94(m，H-2c)，3.46(H-3c)，3.75(m，H-4c)，3.25(d，H-5c)，4.85(br s，H-1d)，4.05(dd，H-2d)，3.43(m，H-3d)，3.73(m，H-4d)，3.35(d，H-5d)，4.83(br s，H-1e)，4.05(dd，H-2e)，3.46(m，H-3e)，3.73(m，H-4e)，3.30(br s，H-5e)，4.50(d，H-1f)，3.92(dd，H-2f)，3.56(m，H-3f)，3.60(m，H-4f)，3.35(d，H-5f)； ¹³ C NMR(150MHz,MeOD)δ：99.5(C-1a)，84.2(C-2a)，69.8(C-3a)，69.5(C-4a)，76.5(C-5a)，60.5(C-6a)，94.2(C-1b)，83.1(C-2b)，76.3(C-3b)，66.0(C-4b)，62.5(C-5b)，91.3(C-1c)，83.1(C-2c)，74.6(C-3c)，64.9(C-4c)，62.6(C-5c)，98.5(C-1d)，78.4(C-2d)，73.8(C-3d)，65.0(C-4d)，62.6(C-5d)，103.5(C-1e)，78.1(C-2e)，73.1(C-3e)，72.0(C-4e)，64.5(C-5e)，105.5(C-1f)，77.3(C-2f)，71.2(C-3f)，63.8(C-4f)，63.5(C-5f)。

Compound 5: yellow powder (methanol); ESI-MS m/z 289[ M-H ]] ^- ； ¹ H NMR(600MHz,MeOD)δ：8.03(4H，s，OH×4)，4.55(1H，d，J＝10.5Hz，H-2)，5.95(1H，d，J＝2.25Hz，H-6)，6.01(1H，d，J＝2.25Hz，H-8)，6.91(1H，br s，H-2′)，6.75(1H，br d，J＝12Hz，H-5′)，6.81(1H，d，J＝12Hz，H-6′)，4.05(1H，br s，OH×3)； ¹³ C NMR(150MHz,MeOD)δ：82.5(C-2)，68.2(C-3)，28.5(C-4)，157.3(C-5)，95.6(C-6)，157.2(C-7)，95.2(C-8)，157.0(C-9)，99.8(C-10)，132.0(C-1′)，115.5(C-2′)，145.4(C-3′)，145.3(C-4′)，115.3(C-5′)，119.3(C-6′)。

Compound 6: yellow needle crystals (dimethyl sulfoxide); ESI-MS m/z 919[2M+Na ]] ⁺ ； ¹ H NMR(600MHz,DMSO)δ：7.55(1H，s，H-5)，7.72(1H，s，H-5′)，3.95(3H，s，-OCH ₃ ),5.00(1H，d，J＝14Hz，H-1")； ¹³ C NMR(150MHz,DMSO)δ：113.2(C-1)，141.5(C-2)，140.1(C-3)，152.4(C-4)，111.3(C-5)，111.3(C-6)，158.7(C-7)，114.1(C-1′)，141.7(C-2′)，135.5(C-3′)，146.5(C-4′)，107.3(C-5′)，111.4(C-6′)，158.5(C-7′)，60.9(C ₃ -OCH ₃ ),102.5(C-1")，72.5(C-2")，75.3(C-3")，69.2(C-4")，65.1(C-5")。

Compound 7: yellow needle crystals (dimethyl sulfoxide); ESI-MS m/z 461[ M-H ]] ^- ； ¹ H NMR(600MHz,DMSO)δ：7.48(1H，s，H-5)，7.60(1H，s，H-5′)，3.95(3H，s，-OCH ₃ ),5.42(1H，s，H-1")； ¹³ C NMR(150MHz,DMSO)δ：107.3(C-1)，140.1(C-2)，136.2(C-3)，146.5(C-4)，111.3(C-5)，111.5(C-6)，158.7(C-7)，114.1(C-1′)，141.7(C-2′)，141.6(C-3′)，152.6(C-4′)，111.6(C-5′)，113.0(C-6′)，158.5(C-7′)，60.9(C ₃ -OCH ₃ ),100.3(C-1")，70.2(C-2")，70.5(C-3")，71.5(C-4")，69.8(C-5"),17.8(C-6")。

Tablet: 10mg of compound 2, 160mg of lactose, 60mg of starch and 20mg of magnesium stearate;

the preparation method comprises the following steps: mixing the extract, lactose and starch, wetting with water, sieving the wet mixture, drying, sieving again, adding magnesium stearate, tabletting the mixture, each tablet weighing 250mg, and the compound content of 10mg.

Example 2

Ampoule agent: 2mg of Compound 1 obtained in example 1,10 mg of sodium chloride;

the preparation method comprises the following steps: the compound and sodium chloride were dissolved in an appropriate amount of water for injection, the resulting solution was filtered and filled into ampoules under sterile conditions.

Example 3

The capsule comprises the following components: 10mg of compound 3 obtained in example 1, 187mg of lactose and 3mg of magnesium stearate;

the preparation method comprises the following steps: compound 3 was mixed with an auxiliary agent, sieved, uniformly mixed, and the resulting mixture was filled into hard gelatin capsules each weighing 200mg, and the active ingredient was 10mg.

To further analyze that compounds 1,2, 3, 4, 5, 6 and 7 have significant inhibitory effect on LPS-induced release of NO by mouse macrophage RAW264.7, the following activity-verifying experiments were performed on the resulting compounds 1,2, 3, 4, 5, 6 and 7:

1. the experimental method comprises the following steps:

(1) MTT method for detecting proliferation activity of cells

And the MTT method is adopted to detect the influence of each monomer compound on the proliferation activity of the mouse macrophage RAW264.7, and the safe and effective molar concentration is screened. Taking cells in logarithmic growth phase, adjusting the cell concentration to 2X 104/ml, inoculating into a 96-well plate, culturing for 24h in a 5% CO2 incubator at 37 ℃ until the cells adhere to the wall, adding liquid medicines with different molar concentrations as administration groups, setting the concentration to 3.125, 6.25, 12.5, 25, 50, 100, 200, 400 and 800 mu mol.L-1, adding blank control (only culture solution) and negative control (containing cells and culture solution), adding 20 mu L of MTT (5 mg/ml PBS solution) into each well, continuously culturing for 4h, absorbing supernatant, adding 150 mu L of DMSO into each well, shaking for 10min in a dark place, and detecting absorbance value at 570 nm.

(2) Detection of NO release amount of mouse mononuclear macrophage by Griess method

The anti-inflammatory activity of each monomeric compound was evaluated using the LPS-induced mouse macrophage RAW264.7 inflammation model. Taking cells in logarithmic growth phase, washing twice with PBS, adding a proper amount of culture medium, blowing uniformly, counting cell plates, adding a complete culture medium to dilute the cell concentration to 1X 105/ml, inoculating into a 96-well plate, culturing for 24 hours, adhering the cells to the wall, adding a sample to be tested diluted by the culture medium into each hole, dividing the sample into dexamethasone (positive control group), LPS (negative control group), blank group and LPS+ drug group, setting 3 compound holes for each concentration to 1 mug/ml, continuously culturing for 24 hours, taking a new 96-well plate, adding 50 mu l of culture solution supernatant into each hole, operating according to the instruction book of an inflammatory factor kit, and determining the release amount of NO. Measuring absorbance value at 540nm with enzyme-labeled instrument, calculating inhibition rate IC of drug to mouse macrophage RAW264.7 inflammatory factor NO release by GraphPad Prism 7 biological statistical software ₅₀ Values.

2. Test results

As can be seen from FIG. 2, the cell proliferation activities of compounds 1,2, 3, 4, 5, 6 and 7 were all greater than 90% at 50. Mu. Mol/L, compared with the blank control, indicating that there was little effect on the proliferation of the mouse macrophage RAW264.7 at a monomer concentration of 50. Mu. Mol/L or less, and the safe concentration range was considered.

As can be seen from fig. 3, NO release after LPS stimulation was significantly higher than that of the control group (P<0.001 And) shows that the molding was successful. Dexamethasone was used as a positive control in the test (median inhibitory concentration IC ₅₀ =22.46 μM), the compounds can reduce the NO release amount at molar concentrations of 3.125, 6.25, 12.5, 25, 50 μmol/L compared with LPS group, and have dose dependence. From the above study, it can be seen that compound 1, compound 2, compound 3, compound 4, compound 5, compound 6 and compound 7 exhibit better anti-inflammatory activity than dexamethasone, a positive drug, IC of each compound ₅₀ The values are shown in Table 1.

TABLE 1 Compounds IC ₅₀ Value summary table

The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the invention in any way, and any simple modification, equivalent variation and variation of the above embodiment according to the technical matter of the present invention still fall within the scope of the technical scheme of the present invention.

Claims

1. An extract composition with anti-inflammatory activity extracted from the rootstock of rosa roxburghii, which is characterized in that: the extraction composition comprises compounds 1-7, and has a structural formula as follows:

the extract composition is prepared by cleaning fresh fructus Rosae Normalis, cutting, reflux-extracting with 80% ethanol for 3 times, filtering, mixing extractive solutions, concentrating under reduced pressure until no ethanol smell exists, and concentrating at 60deg.C.

2. The extract composition with anti-inflammatory activity extracted from the rootstock of rosa roxburghii as claimed in claim 1, wherein the compounds 1-7 are prepared by separating the extract composition from the sample by silica gel column chromatography, and chloroform is selected from the group consisting of: methanol=10: 1,5:1,1:1,0:1 as eluent to obtain four parts, wherein part A, part B, part C and part D; part C was then purified with chloroform: methanol=630:1, 20:1,10:1:1 to afford compound 1 and compound 2; part B was prepared with chloroform: methanol=20:1, 10:1 gradient elution, concentration under reduced pressure, recrystallization to obtain compound 3; part D was purified with chloroform: methanol=8:1 elution to give compound 5; concentrating the other obtained fractions under reduced pressure, and purifying by Sephadex-LH-20 gel chromatographic column chromatography to obtain compound 4, compound 6 and compound 7.

3. An extract composition with anti-inflammatory activity extracted from the rootstock of rosa roxburghii as claimed in claim 1, characterized in that: the root and stem of the Rosa roxburghii is Rosa roxburghii No. 5.

4. Use of an extract composition having anti-inflammatory activity extracted from the rootstock of rosa roxburghii as claimed in claim 1, characterized in that: the extract composition has obvious inhibition effect on NO released by mouse macrophage RAW264.7 induced by LPS, and can be used for preparing anti-inflammatory drugs or veterinary drugs.

5. The use of an extract composition having anti-inflammatory activity extracted from the rootstock of rosa roxburghii as claimed in claim 4, characterized in that: when the extract composition is used as a medicament, it may be used as it is or in the form of a pharmaceutical composition.